Related Experiment Video
Updated: Jan 15, 2026

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
Moyamoya disease: epidemiology, clinical features, pathogenesis, diagnosis and therapeutic interventions
Xinyue Cheng1, Ying Cao1, Junbo Duan1
1Center for Stem Cell and Translational Medicine, School of Life Science, Anhui University, Hefei, 230601, China.
Abstract:
Moyamoya disease (MMD) is a rare cerebrovascular disorder characterized by progressive stenosis of the intracranial internal carotid arteries and the development of compensatory, fragile collateral vascular networks at the skull. Emerging evidence suggests that the pathogenesis of MMD involves genetic/epigenetic predisposition, dysregulated immune responses, and environmental triggers. Notably, the RNF213 p.R4810K variant has been identified as a key genetic susceptibility factor, particularly in East Asian populations. However, the molecular mechanisms underlying disease progression remain incompletely elucidated, primarily due to the limited availability of patient-derived cerebrovascular tissues and the lack of animal models that faithfully recapitulate the full spectrum of human MMD pathology. These constraints have impeded the development of targeted therapeutic interventions. Diagnostically, digital subtraction angiography (DSA) continues to serve as the gold standard for diagnosing MMD, enabling detailed visualization of steno-occlusive lesions and characteristic moyamoya vessels. Current clinical management relies predominantly on surgical revascularization to enhance cerebral perfusion, yet this strategy does not alter the fundamental disease process. Recent advances in patient-derived vascular organoids and serum-stimulated cellular models have facilitated drug screening and biomarker identification. In this review, we provide a systematic overview of the epidemiology, clinical manifestations, and genetic landscape of MMD, with a focus on recent progress in deciphering its molecular basis. We further discuss the transformative potential of induced pluripotent stem cell (iPSC) technology, particularly when combined with CRISPR-based gene editing, for modeling MMD vasculopathy, investigating the functional impact of RNF213 mutations, and exploring precision repair approaches. These innovative approaches offer novel insights into disease mechanisms and open new avenues for therapeutic intervention in MMD.
Insights
Moyamoya disease (MMD) is a rare cerebrovascular disorder. Research is advancing understanding of its genetic basis and molecular mechanisms using stem cell models to develop new therapies.
Area of Science:
- Neuroscience
- Genetics
- Vascular Biology
Background:
- Moyamoya disease (MMD) is a rare cerebrovascular disorder causing progressive stenosis of intracranial arteries.
- Pathogenesis involves genetic factors, immune responses, and environmental triggers, with the RNF213 p.R4810K variant being a key susceptibility factor.
- Limited patient tissues and inadequate animal models hinder understanding and therapeutic development.
Purpose of the Study:
- To provide a systematic overview of MMD epidemiology, clinical features, and genetics.
- To highlight recent progress in deciphering the molecular basis of MMD.
- To discuss the potential of iPSC technology and CRISPR gene editing for MMD research and therapy.
Main Methods:
- Review of existing literature on MMD epidemiology, genetics, and molecular mechanisms.
- Discussion of diagnostic tools like digital subtraction angiography (DSA).
- Exploration of advanced research models including patient-derived vascular organoids and induced pluripotent stem cells (iPSCs).
Main Results:
- The RNF213 p.R4810K variant is a significant genetic factor, particularly in East Asian populations.
- Patient-derived models and iPSC technology offer new avenues for drug screening and biomarker identification.
- Surgical revascularization improves cerebral perfusion but does not alter the underlying disease process.
Conclusions:
- Innovative approaches like iPSC technology combined with CRISPR gene editing are crucial for modeling MMD vasculopathy and investigating RNF213 mutations.
- These advanced techniques provide novel insights into MMD pathogenesis.
- Precision repair strategies and targeted therapies hold promise for future MMD treatment.
More Related Videos
08:56Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes
Published on: October 10, 2025
10:30Surgical Approach for Middle Cerebral Artery Occlusion and Reperfusion Induced Stroke in Mice
Published on: October 20, 2016
Related Concept Videos
Coronary Artery Disease III: Clinical Manifestations
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Coronary Artery Disease II: Pathophysiology
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Aneurysm II: Clinical Manifestations and Diagnostic Studies